Display Settings:

Format

Send to:

Choose Destination
See comment in PubMed Commons below
Maturitas. 2014 Feb;77(2):180-4. doi: 10.1016/j.maturitas.2013.10.017. Epub 2013 Nov 1.

Risk-reducing mastectomy in BRCA1/2 mutation carriers: factors influencing uptake and timing.

Author information

  • 1Departments of Epidemiology, University Medical Center, University of Groningen, Groningen, The Netherlands. Electronic address: cmg.driel@umcg.nl.
  • 2Reconstructive Surgery, University Medical Center, University of Groningen, Groningen, The Netherlands.
  • 3Surgery, University Medical Center, University of Groningen, Groningen, The Netherlands.
  • 4Medical Psychology, University Medical Center, University of Groningen, Groningen, The Netherlands.
  • 5Genetics and University Medical Center, University of Groningen, Groningen, The Netherlands.
  • 6Gynaecology, University Medical Center, University of Groningen, Groningen, The Netherlands.
  • 7Departments of Epidemiology, University Medical Center, University of Groningen, Groningen, The Netherlands. Electronic address: g.h.de.bock@umcg.nl.

Abstract

INTRODUCTION:

Strategies in case of high risk of breast cancer in BRCA1/2 mutation carriers are either intensive breast cancer screening or risk-reducing mastectomy (RRM). Both options have a high physical and psychosexual impact. The aim of this study is to investigate who chooses when to undergo RRM.

METHODS:

BRCA1/2 mutation carriers have been prospectively registered at the family cancer clinic between 1994 and 2011. Analyses were performed to assess the relation between characteristics of the BRCA1/2 mutation carriers and an earlier decision for RRM.

RESULTS:

A cumulative percentage of 35.6% of all women chose to undergo RRM within the first five years after disclosure of DNA test results. Women needed less time to choose for RRM measured from the first visit, if they were younger than 50 years of age (hazard ratio (HR)=2.67, 95% confidence interval (CI)=1.30-5.48) or had a mother who had had breast cancer (HR=1.51 95% CI=1.04-2.18). Also, women needed less time to choose for RRM in case of a previous breast cancer (HR=2.25, 95% CI=1.55-3.27). After a previous unilateral therapeutic mastectomy as a treatment for breast cancer, women needed less time to choose for RRM of the contralateral breast (HR=2.69, 95% CI=1.29-5.62) compared to women who had had breast-conserving therapy.

CONCLUSION:

BRCA1/2 mutation carriers aged under 50, having a mother with breast cancer, who had previous unilateral breast cancer and previous unilateral therapeutic mastectomy chose more often and earlier for RRM.

Copyright © 2013 Elsevier Ireland Ltd. All rights reserved.

KEYWORDS:

Breast neoplasms/prevention & control; Genes, BRCA1; Genes, BRCA2; Mastectomy; Risk reduction behavior; Time factors

PMID:
24268650
[PubMed - in process]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Elsevier Science
    Loading ...
    Write to the Help Desk